Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients

M. Pang, Y. Setoyama, K. Tsuzaka, K. Yoshimoto, K. Amano, T. Abe, Tsutomu Takeuchi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

We have reported that tyrosine phosphorylation and expression of the T cell receptor zeta chain (TCR ζ) was decreased in two systemic lupus erythematosus (SLE) patients with an abnormal TCR ζ lacking exon-7. To examine further the TCR ζ defect and any possible relationship with specific clinical features, we studied the expression of TCR ζ in peripheral blood T cells from 44 patients with SLE, 53 with other rheumatic diseases (30 rheumatoid arthritis (RA), 11 systemic sclerosis (SSc) and 12 primary Sjögren's syndrome(SjS)) and 39 healthy individuals. Flow cytometric analysis demonstrated a significant decrease in the expression of TCR ζ in SLE (P < 0.001), but not in the other rheumatic diseases. Immunoprecipitation experiments confirmed that the expression of TCR ζ in SLE T cells was decreased dramatically (normal: 111.4 ± 22.6%, SLE: 51.6 ± 37.4%,P < 0.0001). The decrease in TCR ζ did not correlate with disease activity, or with the dose of prednisolone (PSL). There were, however, three SLE patients in whom the level of TCR ζ expression normalized after treatment, suggesting that mechanisms responsible for the TCR ζ defect appear to be heterogeneous. These results confirm the defective expression and altered tyrosine phosphorylation of TCR ζ in a large proportion of SLE patients, suggesting that it may play an important role in T cell dysfunction in SLE.

Original languageEnglish
Pages (from-to)160-168
Number of pages9
JournalClinical and Experimental Immunology
Volume129
Issue number1
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

T-Cell Antigen Receptor
Systemic Lupus Erythematosus
Tyrosine
Blood Cells
Phosphorylation
T-Lymphocytes
Rheumatic Diseases
Systemic Scleroderma
Prednisolone
Immunoprecipitation
Exons
Rheumatoid Arthritis

Keywords

  • Autoimmunity
  • Signal transduction
  • TCR-zeta chain
  • Tyrosine phosphorylation

ASJC Scopus subject areas

  • Immunology

Cite this

Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients. / Pang, M.; Setoyama, Y.; Tsuzaka, K.; Yoshimoto, K.; Amano, K.; Abe, T.; Takeuchi, Tsutomu.

In: Clinical and Experimental Immunology, Vol. 129, No. 1, 2002, p. 160-168.

Research output: Contribution to journalArticle

@article{dc6dee8e18384a0087474681a8412144,
title = "Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients",
abstract = "We have reported that tyrosine phosphorylation and expression of the T cell receptor zeta chain (TCR ζ) was decreased in two systemic lupus erythematosus (SLE) patients with an abnormal TCR ζ lacking exon-7. To examine further the TCR ζ defect and any possible relationship with specific clinical features, we studied the expression of TCR ζ in peripheral blood T cells from 44 patients with SLE, 53 with other rheumatic diseases (30 rheumatoid arthritis (RA), 11 systemic sclerosis (SSc) and 12 primary Sj{\"o}gren's syndrome(SjS)) and 39 healthy individuals. Flow cytometric analysis demonstrated a significant decrease in the expression of TCR ζ in SLE (P < 0.001), but not in the other rheumatic diseases. Immunoprecipitation experiments confirmed that the expression of TCR ζ in SLE T cells was decreased dramatically (normal: 111.4 ± 22.6{\%}, SLE: 51.6 ± 37.4{\%},P < 0.0001). The decrease in TCR ζ did not correlate with disease activity, or with the dose of prednisolone (PSL). There were, however, three SLE patients in whom the level of TCR ζ expression normalized after treatment, suggesting that mechanisms responsible for the TCR ζ defect appear to be heterogeneous. These results confirm the defective expression and altered tyrosine phosphorylation of TCR ζ in a large proportion of SLE patients, suggesting that it may play an important role in T cell dysfunction in SLE.",
keywords = "Autoimmunity, Signal transduction, TCR-zeta chain, Tyrosine phosphorylation",
author = "M. Pang and Y. Setoyama and K. Tsuzaka and K. Yoshimoto and K. Amano and T. Abe and Tsutomu Takeuchi",
year = "2002",
doi = "10.1046/j.1365-2249.2002.01833.x",
language = "English",
volume = "129",
pages = "160--168",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients

AU - Pang, M.

AU - Setoyama, Y.

AU - Tsuzaka, K.

AU - Yoshimoto, K.

AU - Amano, K.

AU - Abe, T.

AU - Takeuchi, Tsutomu

PY - 2002

Y1 - 2002

N2 - We have reported that tyrosine phosphorylation and expression of the T cell receptor zeta chain (TCR ζ) was decreased in two systemic lupus erythematosus (SLE) patients with an abnormal TCR ζ lacking exon-7. To examine further the TCR ζ defect and any possible relationship with specific clinical features, we studied the expression of TCR ζ in peripheral blood T cells from 44 patients with SLE, 53 with other rheumatic diseases (30 rheumatoid arthritis (RA), 11 systemic sclerosis (SSc) and 12 primary Sjögren's syndrome(SjS)) and 39 healthy individuals. Flow cytometric analysis demonstrated a significant decrease in the expression of TCR ζ in SLE (P < 0.001), but not in the other rheumatic diseases. Immunoprecipitation experiments confirmed that the expression of TCR ζ in SLE T cells was decreased dramatically (normal: 111.4 ± 22.6%, SLE: 51.6 ± 37.4%,P < 0.0001). The decrease in TCR ζ did not correlate with disease activity, or with the dose of prednisolone (PSL). There were, however, three SLE patients in whom the level of TCR ζ expression normalized after treatment, suggesting that mechanisms responsible for the TCR ζ defect appear to be heterogeneous. These results confirm the defective expression and altered tyrosine phosphorylation of TCR ζ in a large proportion of SLE patients, suggesting that it may play an important role in T cell dysfunction in SLE.

AB - We have reported that tyrosine phosphorylation and expression of the T cell receptor zeta chain (TCR ζ) was decreased in two systemic lupus erythematosus (SLE) patients with an abnormal TCR ζ lacking exon-7. To examine further the TCR ζ defect and any possible relationship with specific clinical features, we studied the expression of TCR ζ in peripheral blood T cells from 44 patients with SLE, 53 with other rheumatic diseases (30 rheumatoid arthritis (RA), 11 systemic sclerosis (SSc) and 12 primary Sjögren's syndrome(SjS)) and 39 healthy individuals. Flow cytometric analysis demonstrated a significant decrease in the expression of TCR ζ in SLE (P < 0.001), but not in the other rheumatic diseases. Immunoprecipitation experiments confirmed that the expression of TCR ζ in SLE T cells was decreased dramatically (normal: 111.4 ± 22.6%, SLE: 51.6 ± 37.4%,P < 0.0001). The decrease in TCR ζ did not correlate with disease activity, or with the dose of prednisolone (PSL). There were, however, three SLE patients in whom the level of TCR ζ expression normalized after treatment, suggesting that mechanisms responsible for the TCR ζ defect appear to be heterogeneous. These results confirm the defective expression and altered tyrosine phosphorylation of TCR ζ in a large proportion of SLE patients, suggesting that it may play an important role in T cell dysfunction in SLE.

KW - Autoimmunity

KW - Signal transduction

KW - TCR-zeta chain

KW - Tyrosine phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=0036379452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036379452&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2249.2002.01833.x

DO - 10.1046/j.1365-2249.2002.01833.x

M3 - Article

C2 - 12100036

AN - SCOPUS:0036379452

VL - 129

SP - 160

EP - 168

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -